Edwards Lifesciences Receives FDA Approval for Tricuspid Valve Repair System
Edwards Lifesciences has secured US FDA approval for its tricuspid valve repair system, marking a significant milestone for its structural heart disease portfolio.
Stocks · News reference
Nike, Synaptics And 3 Stocks To Watch Heading Into Friday
Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
Edwards Lifesciences recalls Commander M delivery systems following balloon burst reports and 1 death. Read the FDA alert.
Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-transcatheter-mitral-valve-delivery-system-issue-edwards-lifesciences
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110
Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.
Mangoceuticals Closes Registered Direct Offering Following $2.5M Strategic Investment Commitment In MangoRx IP Holdings To Support Intellectual Property Commercialization
Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercializationDALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc.
8-K filing — MANGOCEUTICALS, INC. (MGRX)
Filed: 2026-10-09 AccNo: 0001493152-26-046510 Size: 698 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits